| Diabetic neuropathy: clinical manifestations and current treatments BC Callaghan, HT Cheng, CL Stables, AL Smith, EL Feldman The lancet NEUROLOGY 11 (6), 521-534, 2012 | 1349 | 2012 |
| Diabetic neuropathy EL Feldman, BC Callaghan, R Pop-Busui, DW Zochodne, DE Wright, ... Nature reviews Disease primers 5 (1), 1-18, 2019 | 1279 | 2019 |
| Enhanced glucose control for preventing and treating diabetic neuropathy BC Callaghan, AA Little, EL Feldman, RAC Hughes Cochrane database of systematic reviews, 2012 | 751 | 2012 |
| Diabetic neuropathy: cellular mechanisms as therapeutic targets AM Vincent, BC Callaghan, AL Smith, EL Feldman Nature Reviews Neurology 7 (10), 573-583, 2011 | 628 | 2011 |
| Neurological consequences of obesity P D O'Brien, LM Hinder, BC Callaghan, EL Feldman The Lancet Neurology 16 (6), 465-477, 2017 | 452 | 2017 |
| Likelihood of seizure remission in an adult population with refractory epilepsy BC Callaghan, K Anand, D Hesdorffer, WA Hauser, JA French Annals of neurology 62 (4), 382-389, 2007 | 397 | 2007 |
| The endoribonuclease activity of mammalian IRE1 autoregulates its mRNA and is required for the unfolded protein response W Tirasophon, K Lee, B Callaghan, A Welihinda, RJ Kaufman Genes & development 14 (21), 2725-2736, 2000 | 341 | 2000 |
| Distal symmetric polyneuropathy: a review BC Callaghan, RS Price, EL Feldman Jama 314 (20), 2172-2181, 2015 | 306 | 2015 |
| Painful diabetic neuropathy A Peltier, SA Goutman, BC Callaghan Bmj 348, 2014 | 252 | 2014 |
| Diabetic neuropathy: one disease or two? BC Callaghan, J Hur, EL Feldman Current opinion in neurology 25 (5), 536-541, 2012 | 209 | 2012 |
| Risk factors for incident diabetic polyneuropathy in a cohort with screen-detected type 2 diabetes followed for 13 years: ADDITION-Denmark ST Andersen, DR Witte, EM Dalsgaard, H Andersen, P Nawroth, ... Diabetes care 41 (5), 1068-1075, 2018 | 205 | 2018 |
| Metabolic syndrome components are associated with symptomatic polyneuropathy independent of glycemic status BC Callaghan, R Xia, M Banerjee, N de Rekeneire, TB Harris, ... Diabetes care 39 (5), 801-807, 2016 | 197 | 2016 |
| Association between metabolic syndrome components and polyneuropathy in an obese population BC Callaghan, R Xia, E Reynolds, M Banerjee, AE Rothberg, CF Burant, ... JAMA neurology 73 (12), 1468-1476, 2016 | 189 | 2016 |
| Identification of epigenetically altered genes in sporadic amyotrophic lateral sclerosis C Figueroa-Romero, J Hur, DE Bender, CE Delaney, MD Cataldo, ... PloS one 7 (12), e52672, 2012 | 185 | 2012 |
| Diabetes and obesity are the main metabolic drivers of peripheral neuropathy BC Callaghan, LL Gao, Y Li, X Zhou, E Reynolds, M Banerjee, ... Annals of clinical and translational neurology 5 (4), 397-405, 2018 | 184 | 2018 |
| Remission and relapse in a drug‐resistant epilepsy population followed prospectively B Callaghan, M Schlesinger, W Rodemer, J Pollard, D Hesdorffer, ... Epilepsia 52 (3), 619-626, 2011 | 176 | 2011 |
| Association of environmental toxins with amyotrophic lateral sclerosis FC Su, SA Goutman, S Chernyak, B Mukherjee, BC Callaghan, ... JAMA neurology 73 (7), 803-811, 2016 | 156 | 2016 |
| Practice guideline: Cervical and ocular vestibular evoked myogenic potential testing: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the … TD Fife, JG Colebatch, KA Kerber, K Brantberg, M Strupp, H Lee, ... Neurology 89 (22), 2288-2296, 2017 | 150 | 2017 |
| The metabolic syndrome and neuropathy: therapeutic challenges and opportunities B Callaghan, E Feldman Annals of neurology 74 (3), 397-403, 2013 | 145 | 2013 |
| An imbalance between excitatory and inhibitory neurotransmitters in amyotrophic lateral sclerosis revealed by use of 3-T proton magnetic resonance spectroscopy BR Foerster, MG Pomper, BC Callaghan, M Petrou, RAE Edden, ... JAMA neurology 70 (8), 1009-1016, 2013 | 142 | 2013 |
